A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 1

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Comparator: Placebo to MK6349; Drug: MK6349

Study type: Interventional

Funder types: Industry

Identifiers

NCT00943371

2007_597

MK6349-002

6349-002

Details and patient eligibility

About

A single dose study to assess the safety, tolerability, pharmacokinetics and pharmacokinetics of MK6349 in Type 2 Diabetics.

Enrollment: 28 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject is a non-smoking male or female (females must be postmenopausal, had a tubal ligation or a hysterectomy) between 18 to 55 years of age
• Subject has Type 2 Diabetes and is currently being treated with diet and exercise alone or with less than 3 oral diabetes drugs

Exclusion criteria

• Subject is on insulin or a PPAR agonist medication
• Subject has Type 1 diabetes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

28 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

MK6349

Treatment:

Drug: MK6349

2

Placebo Comparator group

Description:

Placebo to MK6349

Treatment:

Drug: Comparator: Placebo to MK6349